RNAi 기술 시장 규모, 점유율 및 동향 분석 리포트 : 제품 및 서비스별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

RNAi Technology Market Summary

The global RNAi technology market size was estimated at USD 2.94 billion in 2024 and is projected to reach USD 9.52 billion by 2033, growing at a CAGR of 14.25% from 2025 to 2033. This market growth is attributed to the increasing prevalence of autoimmune diseases, rare disorders, and cancer across the globe.

Expansion of RNAi-Based Therapeutics

The RNAi technology market is growing rapidly due to strong clinical validation and multiple FDA/EMA approvals, including ONPATTRO, GIVLAARI, OXLUMO, and AMVUTTRA. These approvals have proven that RNAi can be developed into safe and effective therapeutics, boosting confidence among biopharma companies and accelerating investment in RNAi platforms. Its ability to precisely silence disease-causing genes makes RNAi a transformative option for rare genetic and liver-targeted disorders. As approved RNAi therapies show strong clinical and commercial performance, demand for RNAi tools, reagents, and delivery technologies continues to rise.

The growth of the market is being further accelerated by significant pharmaceutical interest. Through partnerships, acquisitions, and internal research and development, businesses such as Alnylam, Arrowhead, Dicerna (Novo Nordisk), AstraZeneca, and Takeda are growing their RNAi pipelines. Through these initiatives, RNAi applications are expanding into the fields of oncology, infectious diseases, and cardiometabolic disorders. Significant investments, enduring collaborations, and specialized RNAi research facilities are propelling clinical activity, product launches, and ongoing innovation. The need for RNAi platforms in drug discovery and clinical development keeps growing as the therapeutic pipeline broadens and industry investment increases.

Advancements in Delivery Technologies

Advances in RNAi delivery systems have become a key growth driver for the RNAi technology industry. Earlier issues, such as poor uptake, rapid degradation, and off-target effects, have been largely addressed through innovations in LNPs, GalNAc-siRNA conjugates, polymer carriers, and viral vectors. These next-generation platforms enhance stability, biodistribution, and tissue-specific targeting, particularly in the liver, a major site for genetic and metabolic disorders. As delivery becomes more efficient and clinically viable, demand for RNAi reagents, delivery kits, and development solutions continues to increase.

In addition, RNAi is expanding beyond liver targets owing to advanced delivery technologies. New strategies, such as targeted nanoparticles, peptide-based carriers, and engineered exosomes, are creating opportunities for applications in infectious diseases, cancer, and the central nervous system. To improve their pipelines and lower development risk, biopharma companies are making significant investments in these delivery innovations.

Global RNAi Technology Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global RNAi technology market report on the basis of product & service, application, end use, and region:

• Product & Service Outlook (Revenue, USD Million, 2021 - 2033)
• Products
  • miRNA
  • siRNA
  • Others
• Service
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Drug Discovery & Development
  • Neurology
  • Oncology
  • Infectious Diseases
  • Metabolic Diseases
  • Others
• Functional Genomics
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• CROs & CMOs
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product & Service
  • 1.2.2. Application
  • 1.2.3. End Use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Expansion of RNAi-based therapeutics
    • 3.2.1.2. Advancements in delivery technologies
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Lack of skilled professionals and research support in developing countries
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis

Chapter 4. RNAi Technology Market: Product & Service Business Analysis

• 4.1. Product & Service Segment Dashboard
• 4.2. Global RNAi Technology Market Product & Service Movement Analysis
• 4.3. Global RNAi Technology Market Size & Trend Analysis, by Product & Service, 2021 to 2033 (USD Million)
• 4.4. Products
  • 4.4.1. Global Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. miRNA
    • 4.4.2.1. Global miRNA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. siRNA
    • 4.4.3.1. Global siRNA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.4. Others
    • 4.4.4.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Services
  • 4.5.1. Global Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. RNAi Technology Market: Application Business Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global RNAi Technology Market Application, Movement Analysis
• 5.3. Global RNAi Technology Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Drug Discovery & Development
  • 5.4.1. Global Drug Discovery & Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. Neurology
    • 5.4.2.1. Global Neurology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. Oncology
    • 5.4.3.1. Global Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.4. Infectious Diseases
    • 5.4.4.1. Global Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.5. Metabolic Diseases
    • 5.4.5.1. Global Metabolic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.6. Others
    • 5.4.6.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Functional Genomics
  • 5.5.1. Global Functional Genomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Others
  • 5.6.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. RNAi Technology Market: End Use Business Analysis

• 6.1. End Use Segment Dashboard
• 6.2. Global RNAi Technology Market End Use Movement Analysis
• 6.3. Global RNAi Technology Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Pharmaceutical & Biotechnology Companies
  • 6.4.1. Global Pharmaceutical & Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Academic & Research Institutes
  • 6.5.1. Global Academic & Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. CROs & CMOs
  • 6.6.1. Global CROs & CMOs Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. RNAi Technology Market: Regional Estimates & Trend Analysis by Product & Services, Application, & End Use

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
• 7.3. North America
  • 7.3.1. North America RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Canada RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Mexico RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. UK RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Germany RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. France RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Italy RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Spain RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Denmark RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Framework
    • 7.4.8.4. Sweden RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Regulatory Framework
    • 7.4.9.4. Norway RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Japan RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. China RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. India RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Australia RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Thailand RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. South Korea
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. South Korea RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Brazil RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Argentina RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Middle East & Africa
  • 7.7.1. Middle East & Africa RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. South Africa RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Saudi Arabia RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. UAE RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Kuwait RNAi Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Participant's Overview
  • 8.4.1. Thermo Fisher Scientific, Inc.
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. Merck KGaA
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Creative Biolabs
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. GenScript
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Revvity
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Promega Corporation
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. OriGene Technologies, Inc.
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. Altogen Biosystems
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Danaher
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Bioneer Corporation
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives